The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
Abstract
In paroxysmal nocturnal hemoglobinuria (PNH) hemolytic anemia is due mainly to deficiency of the complement regulator CD59 on the surface of red blood cells (RBCs). Eculizumab, an antibody that targets complement fraction 5 (C5), has proven highly effective in abolishing complement-mediated intravascular hemolysis in PNH; however, the hematologic benefit varies considerably among patients. In the aim to understand the basis for this variable response, we have investigated by flow cytometry the binding of complement fraction 3 (C3) on RBCs from PNH patients before and during eculizumab treatment. There was no evidence of C3 on RBCs of untreated PNH patients; by contrast, in all patients on eculizumab (n = 41) a substantial fraction of RBCs had C3 bound on their surface, and this was entirely restricted to RBCs with the PNH phenotype (CD59−). The proportion of C3+ RBCs correlated significantly with the reticulocyte count and with the hematologic response to eculizumab. In 3 patients in whom 51Cr labeling of RBCs was carried out while on eculizumab, we have demonstrated reduced RBC half-life in vivo, with excess 51Cr uptake in spleen and in liver. Binding of C3 by PNH RBCs may constitute an additional disease mechanism in PNH, strongly enhanced by eculizumab treatment and producing a variable degree of extravascular hemolysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Cited by
Paroxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2014) · Blood · doi:10.1182/blood-2014-02-522128 · Cited by 648
Kelly, R. J., Hill, A., Arnold, L. M., Brooksbank, G. L., Richards, S. J., Cullen, M., Mitchell, L. D., Cohen, D. R., Gregory, W. M., & Hillmen, P. (2011) · Blood · doi:10.1182/blood-2011-02-333997 · Cited by 526
Thrombosis in paroxysmal nocturnal hemoglobinuria
Hill, A., Kelly, R. J., & Hillmen, P. (2013) · Blood · doi:10.1182/blood-2012-09-311381 · Cited by 478
Paroxysmal nocturnal haemoglobinuria
Hill, A., DeZern, A. E., Kinoshita, T., & Brodsky, R. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.28 · Cited by 448
Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria
Hillmen, P., Szer, J., Weitz, I., Röth, A., Höchsmann, B., Panse, J., Usuki, K., Griffin, M., Kiladjian, J.-J., de Castro, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029073 · Cited by 440
Self-citation
Metadata
- Authors
- Risitano, A. M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Alfinito, F., Camera, A., Gianfaldoni, G., Amendola, A., Boschetti, C., Di Bona, E., Fratellanza, G., Barbano, F., Rodeghiero, F., Zanella, A., Iori, A. P., Selleri, C., Luzzatto, L., & Rotoli, B.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-04-23
- Volume
- 113
- Issue
- 17
- Pages
- 4094-4100
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2081653014
- Cited by
- 361
- References
- 1
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. https://app.cochat.ai/papers/10.1182/blood-2008-11-189944
- The paper
- Risitano, A. M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Alfinito, F., Camera, A., Gianfaldoni, G., Amendola, A., Boschetti, C., Di Bona, E., Fratellanza, G., Barbano, F., Rodeghiero, F., Zanella, A., Iori, A. P., Selleri, C., . . . Rotoli, B. (2009). Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. https://doi.org/10.1182/blood-2008-11-189944
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.